Get started
Author

Amy Handlogten

OpenAlex ID: A5035532695
Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial
2019 · Naseema Gangat, Christian Marinaccio, et al. · Clinical Cancer Research · 77
Osteopontin (OPN/SPP1) isoforms collectively enhance tumor cell invasion and dissemination in esophageal adenocarcinoma
2015 · Jules Lin, Amy L. Myers, et al. · Oncotarget · 65
PDF
Alisertib (MLN8237), an Oral Selective Inhibitor of Aurora Kinase a, Has Clinical Activity and Restores GATA1 Expression in Patients with Myelofibrosis
2018 · Naseema Gangat, Brady Lee Stein, et al. · Blood · 9
Supplementary Data from Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial
2023 · Naseema Gangat, Christian Marinaccio, et al.
PDF
Data from Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial
2023 · Naseema Gangat, Christian Marinaccio, et al.
Data from Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial
2023 · Naseema Gangat, Christian Marinaccio, et al.
Supplementary Data from Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial
2023 · Naseema Gangat, Christian Marinaccio, et al.
Works count: 7
Citation count: 151
H-index: 3
I10-index: 2
Year
Topic
Type